Carving out CGTs for payment systems involving government intervention may be an answer
Anne Runyan, Two Labs Pharma Services
Advertisement
Articles by Anne Runyan, Two Labs Pharma Services
Advertisement
Latest Updated Articles
- Innovative models to address cell- and gene-therapy (CGT) payer challenges
Published: May 1st 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Lilly Agreement With Trump Administration Reshapes Patient Access to GLP-1 Obesity Medicines
2
Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?
3
Mark Cuban Cost Plus Drug Company Adds Starjemza to Prescription Drug Portfolio
4
The New Pharma Equation: How DTP, DTC, and DTE are Re-Wiring Healthcare Around Patients
5
